These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 37643637)
1. Molecular Classification Improves Therapeutic Options for Infants and Young Children With Medulloblastoma. Bagchi A; Dhanda SK; Dunphy P; Sioson E; Robinson GW J Natl Compr Canc Netw; 2023 Aug; 21(10):1097-1105. PubMed ID: 37643637 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. Erker C; Mynarek M; Bailey S; Mazewski CM; Baroni L; Massimino M; Hukin J; Aguilera D; Cappellano AM; Ramaswamy V; Lassaletta A; Perreault S; Kline CN; Rajagopal R; Michaiel G; Zapotocky M; Santa-Maria Lopez V; La Madrid AM; Cacciotti C; Sandler ES; Hoffman LM; Klawinski D; Khan S; Salloum R; Hoppmann AL; Larouche V; Dorris K; Toledano H; Gilheeney SW; Abdelbaki MS; Wilson B; Tsang DS; Knipstein J; Oren MY; Shah S; Murray JC; Ginn KF; Wang ZJ; Fleischhack G; Obrecht D; Tonn S; Harrod VL; Matheson K; Crooks B; Strother DR; Cohen KJ; Hansford JR; Mueller S; Margol A; Gajjar A; Dhall G; Finlay JL; Northcott PA; Rutkowski S; Clifford SC; Robinson G; Bouffet E; Lafay-Cousin L J Clin Oncol; 2023 Apr; 41(10):1921-1932. PubMed ID: 36548930 [TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy. Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704 [TBL] [Abstract][Full Text] [Related]
4. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups. Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ; Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563 [TBL] [Abstract][Full Text] [Related]
5. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. Yeo KK; Margol AS; Kennedy RJ; Hung L; Robison NJ; Dhall G; Asgharzadeh S J Neurooncol; 2019 Nov; 145(2):375-383. PubMed ID: 31621042 [TBL] [Abstract][Full Text] [Related]
7. Rapid diagnosis of medulloblastoma molecular subgroups. Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292 [TBL] [Abstract][Full Text] [Related]
8. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199 [TBL] [Abstract][Full Text] [Related]
9. Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups. Tonn S; Korshunov A; Obrecht D; Sill M; Spohn M; von Hoff K; Milde T; Pietsch T; Goschzik T; Bison B; Juhnke BO; Struve N; Sturm D; Sahm F; Bockmayr M; Friedrich C; von Bueren AO; Gerber NU; Benesch M; Jones DTW; Kool M; Wefers AK; Schüller U; Pfister SM; Rutkowski S; Mynarek M Neuro Oncol; 2023 Aug; 25(8):1518-1529. PubMed ID: 36715306 [TBL] [Abstract][Full Text] [Related]
10. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Northcott PA; Hielscher T; Dubuc A; Mack S; Shih D; Remke M; Al-Halabi H; Albrecht S; Jabado N; Eberhart CG; Grajkowska W; Weiss WA; Clifford SC; Bouffet E; Rutka JT; Korshunov A; Pfister S; Taylor MD Acta Neuropathol; 2011 Aug; 122(2):231-40. PubMed ID: 21681522 [TBL] [Abstract][Full Text] [Related]
11. Molecular progression of SHH-activated medulloblastomas. Korshunov A; Okonechnikov K; Sahm F; Ryzhova M; Stichel D; Sievers P; Meyer J; Schrimpf D; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; von Deimling A; Kool M Acta Neuropathol; 2019 Aug; 138(2):327-330. PubMed ID: 31030238 [No Abstract] [Full Text] [Related]
12. Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. Baroni LV; Sampor C; Gonzalez A; Lubieniecki F; Lamas G; Rugilo C; Bartels U; Heled A; Smith KS; Northcott PA; Bouffet E; Alderete D; Ramaswamy V Neuro Oncol; 2020 Dec; 22(12):1873-1881. PubMed ID: 32413139 [TBL] [Abstract][Full Text] [Related]
13. Stem-Like Cell Populations, p53-Pathway Activation and Mechanisms of Recurrence in Sonic Hedgehog Medulloblastoma. Treisman D; Li Y; Zhu Y Neuromolecular Med; 2022 Mar; 24(1):13-17. PubMed ID: 34165693 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping. Gupta T; Maitre M; Sastri GJ; Krishnatry R; Shirsat N; Epari S; Sahay A; Chinnaswamy G; Patil V; Shetty P; Moiyadi A J Neurooncol; 2019 Sep; 144(2):283-291. PubMed ID: 31236820 [TBL] [Abstract][Full Text] [Related]
15. Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure. Gupta T; Pervez S; Dasgupta A; Chatterjee A; Epari S; Chinnaswamy G; Jalali R Clin Cancer Res; 2022 Oct; 28(19):4180-4185. PubMed ID: 35653134 [TBL] [Abstract][Full Text] [Related]
16. Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas. Menyhárt O; Győrffy B Ann Clin Transl Neurol; 2019 May; 6(5):990-1005. PubMed ID: 31139698 [TBL] [Abstract][Full Text] [Related]
17. Medulloblastoma: From Myth to Molecular. Ramaswamy V; Taylor MD J Clin Oncol; 2017 Jul; 35(21):2355-2363. PubMed ID: 28640708 [TBL] [Abstract][Full Text] [Related]
18. Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience. Massimino M; Casanova M; Polastri D; Biassoni V; Modena P; Pecori E; Schiavello E; De Pava MV; Indini A; Rampini P; Bauer D; Catania S; Podda M; Gandola L Childs Nerv Syst; 2013 Jul; 29(7):1107-12. PubMed ID: 23595805 [TBL] [Abstract][Full Text] [Related]
19. Medulloblastoma: an Old Diagnosis with New Promises. Szalontay L; Khakoo Y Curr Oncol Rep; 2020 Jul; 22(9):90. PubMed ID: 32643099 [TBL] [Abstract][Full Text] [Related]
20. Management of pediatric and adult patients with medulloblastoma. Martin AM; Raabe E; Eberhart C; Cohen KJ Curr Treat Options Oncol; 2014 Dec; 15(4):581-94. PubMed ID: 25194927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]